- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Mean clearance (CL) and volume of distribution (Vdss) of imipenem were approximately 45% higher in pediatric patients (3 months to 14 years) than in adults. [SmPC]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Bacterial infections |
|---|
|
| Infection in cystic fibrosis |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Dose adjustment not neededGFR 30-50 ml/min/1.73 m2
Dose adjustment not neededGFR 10-30 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 12 uurGFR < 10 ml/min/1.73 m2
A general recommendation is not providedA second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Imipenem / cilastatin accumulates in patients with renal impairment. If the dose is not adjusted to kidney function, side effects to the central nervous system may occur. Special attention should be paid to neurological symptoms or convulsions in children with known risk factors for seizures, or who use concomitant drugs that lower the seizure threshold.
Use is not recommended for CNS infections. [Ref.]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| First-generation cephalosporins | ||
|---|---|---|
| J01DB05 | ||
| J01DB04 | ||
| J01DB01 | ||
| J01DB03 | ||
| Second-generation cephalosporins | ||
|---|---|---|
| J01DC04 | ||
| J01DC03 | ||
| J01DC02 | ||
| Third-generation cephalosporins | ||
|---|---|---|
| J01DD08 | ||
| J01DD01 | ||
| J01DD13 | ||
| J01DD52 | ||
| J01DD02 | ||
| J01DD14 | ||
| J01DD04 | ||
| Fourth-generation cephalosporins | ||
|---|---|---|
| J01DE01 | ||
| Monobactams | ||
|---|---|---|
| J01DF01 | ||
| Carbapenems | ||
|---|---|---|
| J01DH03 | ||
| J01DH02 | ||
| MONOBACTAMS | ||
|---|---|---|
| J01DF01 | ||
| Other cephalosporins and penems | ||
|---|---|---|
| J01DI02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
- Merck Sharp & Dohme B.V., SPC Tienam (RVG 11089) 19-11-2020, www.geneesmiddeleninformatiebank.nl
- AVOXA ABDA-Datenbank, Interaktionen Impinemen_Cilastatin, accessed 07-2018
- MSD SHARP & DOHME GMBH, SmPC Zienam 500mg/500mg Pulver zur Herstellung einer Infusionslösung (4697.01.00), 11/2015
- Fresenius Kabi, SmPC Imipenem/Cilastatin 500mg/500mg Pulver zur Herstellung einer Infusionslösung (71957.00.00), 08/2012
- UpToDate® Pediatric Drug information, Imipenem/Cilastatin Lexicomp® Version 132.0, accessed 07/2018
- AVOXA ABDA-Datenbank, Interaktionen Impinemen_Cilastatin, accessed 07-2018
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
